MACSF

COMMUNIQUÉS West-GlobeNewswire

Aurora Spine Announces Participation in 7th Annual American Society of Pain & Neuroscience Conference
15/07/2025
CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, [...]
Neuronetics Appoints New Chief Financial Officer
15/07/2025
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process [...]
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
15/07/2025
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal [...]
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
15/07/2025
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used [...]
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
15/07/2025
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
15/07/2025
- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U. [...]
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
15/07/2025
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the [...]
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
15/07/2025
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor [...]
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
15/07/2025
– Mean weight loss of 19.2% at 6 mg with no plateau in 48-week Phase 3 trial – – Favorable safety profile consistent with other GLP-1-based treatments – – Hengrui to submit NDA in China; Kailera plans to evaluate both [...]
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
15/07/2025
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW [...]
Polyrizon Retains Nasdaq Listing Following Hearings Panel
15/07/2025
Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
15/07/2025
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The [...]
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
15/07/2025
Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., [...]
Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
15/07/2025
Landmark MUSIC-DMD Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failure BOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage [...]
HealthLynked Engages Meridian Group to Accelerate Strategic Partnerships and Revenue Growth
15/07/2025
NAPLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. ( OTCQB: HLYK ), a leader in healthcare technology and patient engagement solutions, today announced that it has engaged Meridian Group, a [...]
Extendicare Announces July 2025 Dividend of C$0.042 per Share
15/07/2025
MARKHAM, Ontario, July 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies
15/07/2025
Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ROCKVILLE, Md., July 15, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage [...]
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
15/07/2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it [...]
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
15/07/2025
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid tumors BASKING RIDGE, N. [...]

Pages